Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on La Newsletter de Momentum’s Substack by Mexican Investor. In this article, we will summarize the bulls’ thesis on HIMS.

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...

In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news. Market Domination hosts Madison Mills and Josh Schafer discuss the news and Citi's take on it.

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

In the latest market close, Hims & Hers Health, Inc. (HIMS) reached $18.95, with a -1.86% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Hims & Hers shares have surged this year ... Another example is that there are over 30 million Americans with erectile dysfunction. The company would see substantial growth if a tiny number ...